Author

T. Moyo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Crowther· 1 shared F. Ayres· 1 shared G. Gray· 1 shared G. van Roey· 1 shared H. Schuitemaker· 1 shared J. Sadoff· 1 shared L. Morris· 1 shared L.-G. Bekker· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. Crowther

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology